Skip to main content

Analysts Raise Targets on Affymetrix's Stock but Remain Cautious

NEW YORK (GenomeWeb News) – Analysts today upped their price targets on Affymetrix's stock, after the firm posted revenues and net income that surpassed analysts' consensus estimate.

After the close of the market yesterday, Affy reported total second-quarter revenue of $81.6 million, compared to $86.9 million in the comparable period of 2008. Though the revenues declined year over year, the results easily beat analysts' consensus estimates on both the top and bottom lines.

Following the release of its results, Affy's shares soared on the Nasdaq, and at least a couple of analysts raised their price targets on the firm's shares. However, they remain cautious about the firm's turnaround.

"The apparent stabilization of Affymetrix's business continues the trend we saw last quarter, though we still remain cautious on the company's turnaround," wrote Thomas Weisel Partners analyst Peter Lawson in a research note. "While we continue to see improvement in execution, we are waiting to see more consistency in their operations and clear signs of a turnaround before becoming more constructive."

Lawson increased his third-quarter revenues estimates for the firm to $79 million from $75 million. He also increased his 12-month price target on the firm's shares to $6 from $5.

Likewise, Isaac Ro, an analyst with Leerink Swann, wrote, "Exeecution is improving but we remain cautious on the long-term viability of new products before becoming more constructive on Affymetrix shares but raise our valuation to $7." Ro previously had a price target of $5 on the stock.

In mid-afternoon trade on the Nasdaq, Affy's shares were up 36 percent at $8.02.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.